Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

21
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
21
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

14
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
14
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

660
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
660
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

21
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
21
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

20
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
20
Cardiopulmonary Resuscitation III: AED Use01:23

Cardiopulmonary Resuscitation III: AED Use

46
Introduction to AEDAn Automated External Defibrillator (AED) is a portable medical device that analyzes the heart's rhythm and, if necessary, delivers an electrical shock to help the heart re-establish an effective rhythm during sudden cardiac arrest (SCA). SCA occurs when the heart suddenly and unexpectedly stops beating, leading to a loss of blood flow to the brain and other vital organs. In such emergencies, time is of the essence, and using an AED, combined with Cardiopulmonary...
46

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Validation and implementation of ambulatory obstructive sleep apnea polygraphy screening combined with wearable semi-continuous heart rhythm monitoring in patients with atrial fibrillation: a validation and a pilot study.

Frontiers in cardiovascular medicine·2026
Same author

Comparative performance of wearable ECG devices for rhythm monitoring in endurance athletes.

American journal of preventive cardiology·2026
Same author

Incidence, Mechanistic Insights, and Ablation of Atrial Tachycardia Occurring After Pulsed Field Ablation for Atrial Fibrillation: Results From a Large International Registry.

JACC. Clinical electrophysiology·2026
Same author

Standardized processing of explanted hearts after stereotactic arrhythmia radiotherapy (Bio-STAR): a STOPSTORM framework and first human findings.

European heart journal open·2026
Same author

Real-time IVUS-guided retrieval of a coronary retained guidewire fragment: A case report.

Radiology case reports·2026
Same author

Cluster analysis: an overview of traditional and novel approaches for health researchers.

European journal of cardiovascular nursing·2026

Related Experiment Video

Updated: Aug 8, 2025

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
16:40

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation

Published on: February 28, 2012

26.3K

Implantable cardiac defibrillators in octogenarians.

Maarten Pauwelyn1, Sebastian Ingelaere1,2, Ruben Hoffmann3

  • 1University Hospitals Leuven, Cardiology, Leuven, Belgium.

Journal of Geriatric Cardiology : JGC
|March 6, 2023
PubMed
Summary

Implantable cardiac defibrillator (ICD) implantation in octogenarians showed 11% 1-year mortality. Advanced age, oncological history, secondary prevention, and lower ejection fraction predicted worse outcomes in this elderly population.

More Related Videos

Implantation of Total Artificial Heart in Congenital Heart Disease
07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

24.7K
Implantation of the Syncardia Total Artificial Heart
16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

35.4K

Related Experiment Videos

Last Updated: Aug 8, 2025

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
16:40

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation

Published on: February 28, 2012

26.3K
Implantation of Total Artificial Heart in Congenital Heart Disease
07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

24.7K
Implantation of the Syncardia Total Artificial Heart
16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

35.4K

Area of Science:

  • Cardiology
  • Geriatric Medicine
  • Medical Device Technology

Background:

  • Implantable cardiac defibrillator (ICD) implantation in elderly patients (over 80 years) is a subject of ongoing debate.
  • Limited data exists on the specific outcomes of ICD implantation in octogenarians within Belgium.

Purpose of the Study:

  • To analyze the implantation experience and outcomes of patients over 80 years old who received an ICD in Belgium.
  • To identify predictors of mortality in this specific elderly cohort.

Main Methods:

  • Utilized data from the national QERMID-ICD registry for implantations between February 2010 and March 2019.
  • Analyzed patient characteristics, prevention type, device settings, and all-cause mortality.
  • Employed multivariable Cox proportional hazard regression to determine mortality predictors.

Main Results:

  • 704 octogenarians underwent primary ICD implantation (median age 82).
  • 35% of patients died during a mean follow-up of 3.1 years, with 11% mortality within the first year.
  • Independent predictors for 1-year mortality included advanced age, oncological history, secondary prevention, and lower left ventricular ejection fraction (LVEF).
  • Overall mortality was associated with age, atrial fibrillation history, center volume, and oncological history, with higher LVEF being protective.

Conclusions:

  • Primary ICD implantation in octogenarians is infrequent in Belgium.
  • Significant predictors of increased 1-year and overall mortality in this population include advanced age, oncological history, secondary prevention, and impaired LVEF.